Formulations That Meet Unmet Patient Needs
Focused on long acting
Developing Finished Dosage Forms and a Portfolio of APIs
Fully integrated GMP
Pipeline of Multiple Late Stage Products
In Phase III for RMS and Phase II for
PPMS for treating MS
We are a clinical stage pharmaceutical company, developing complex active pharmaceutical ingredients.
Our main focus is on developing long acting depot injectable drugs.
Our lead programs are GA Depot for treating various forms of MS and long acting Pregabalin (Lyrica®) for pain.
Mapi Pharma to Present Series of Recent Advancements for Treating Multiple Sclerosis (MS) at ECTRIMS 2021
Results for Glatiramer Acetate (GA) Depot Phase IIa study in patients with primary progressive multiple sclerosis, and novel anti-BMP for remyelination treatment in MS will be presented ECTRIMS 2021 Digital Experience will be held virtually Oct. 13-15, 2021 ...
Patient recruitment in Phase III trial has surpassed 60% Trial is expanded to Israel with first clinical site at Tel Aviv Medical Center NESS ZIONA, Israel – Dec. 21, 2020 – Mapi Pharma Ltd., a fully integrated, late clinical stage biopharmaceutical company,...